Abstract
Objective: To analyze the effect of granulocyte colony-stimulating factor (G-CSF) on outcomes in patients with acute myeloid leukemia (AML). Methods: A total of 526 patients with AML in the Haematology Department were enrolled. They were divided into a G-CSF treatment group and a no G-CSF group according to whether G-CSF was administered in the induction chemotherapy period, with 355 cases in the G-CSF group and 171 cases in the no G-CSF group. Cox regression analysis and Kaplan-Meier curve analysis were used to analyze the effect of G-CSF on the first complete remission (CR1) phase and overall survival (OS). In addition, further analysis was performed based on an initial white blood cell count of 50 * 10^9/L. Results: The application of G-CSF significantly shortened the CR1 phase and OS in patients with high leukocytes. Conclusions: G/GM-CSF should be used with caution in patients with AML, especially those with high leukocytes.
Author supplied keywords
Cite
CITATION STYLE
Weng, P., Yang, S., Xu, S., Zhang, S., Wu, Y., & Chen, Y. (2023). Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor. Hematology (United Kingdom), 28(1). https://doi.org/10.1080/16078454.2023.2220521
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.